Search results for "chemoradiotherapy"

showing 10 items of 120 documents

Second St. Gallen European Organisation for Research and Treatment of Cancer Gastrointestinal Cancer Conference: consensus recommendations on controv…

2016

Contains fulltext : 171468pub.pdf (Publisher’s version ) (Open Access) Primary treatment of rectal cancer was the focus of the second St. Gallen European Organisation for Research and Treatment of Cancer (EORTC) Gastrointestinal Cancer Conference. In the context of the conference, a multidisciplinary international expert panel discussed and voted on controversial issues which could not be easily answered using published evidence. Main topics included optimal pretherapeutic imaging, indication and type of neoadjuvant treatment, and the treatment strategies in advanced tumours. Here we report the key recommendations and summarise the related evidence. The treatment strategy for localised rect…

Cancer ResearchStagingColorectal cancermedicine.medical_treatmentNeoplasias Gastrointestinais030230 surgerySYNCHRONOUS LIVER METASTASESImagingCOLORECTAL-CANCER0302 clinical medicineADJUVANT CHEMOTHERAPYTumours of the digestive tract Radboud Institute for Molecular Life Sciences [Radboudumc 14]SHORT-COURSE RADIOTHERAPYRectal cancerNeoadjuvant therapyGastrointestinal NeoplasmsRectal Neoplasms/drug therapyCombination chemotherapyChemoradiotherapyCombined Modality TherapyTotal mesorectal excisionNeoadjuvant TherapyEuropeNeoplasias do Recto/quimioterapiaOncology030220 oncology & carcinogenesisMEDIAN FOLLOW-UPLife Sciences & BiomedicineDiagnostic Imagingmedicine.medical_specialtyAntineoplastic AgentsLOCAL RECURRENCERisk AssessmentCOURSE PREOPERATIVE RADIOTHERAPY03 medical and health sciencesmedicineHumansGastrointestinal cancerOncology & CarcinogenesisRadiochemotherapyNeoplasm StagingScience & TechnologyRadiotherapyRectal Neoplasmsbusiness.industryGeneral surgeryTOTAL MESORECTAL EXCISIONCancerRANDOMIZED PHASE-IIImedicine.diseaseSurgeryRadiation therapySurgerybusiness1112 Oncology And CarcinogenesisChemoradiotherapyPOSTOPERATIVE CHEMORADIOTHERAPY
researchProduct

Improved inter-observer agreement of an expert review panel in an oncology treatment trial--Insights from a structured interventional process.

2015

Abstract Purpose Oncologic imaging is a key for successful cancer treatment. While the quality assurance (QA) of image acquisition protocols has already been focussed, QA of reading and reporting offers still room for improvement. The latter was addressed in the context of a prospective multicentre trial on fluoro-deoxyglucose (FDG)–positron-emission tomography (PET)/CT-based chemoradiotherapy for locally advanced non-small cell lung cancer (NSCLC). Material and methods An expert panel was prospectively installed performing blinded reviews of mediastinal NSCLC involvement in FDG–PET/CT. Due to a high initial reporting inter-observer disagreement, the independent data monitoring committee (I…

Cancer Researchmedicine.medical_specialtyLung NeoplasmsContext (language use)Sensitivity and SpecificityDouble-Blind MethodFluorodeoxyglucose F18Carcinoma Non-Small-Cell LungOutcome Assessment Health CaremedicineData monitoring committeeHumansMedical physicsObserver VariationPET-CTmedicine.diagnostic_testbusiness.industryReproducibility of ResultsChemoradiotherapyClinical trialOncologyPositron emission tomographyPositron-Emission TomographyRadiologybusinessTomography X-Ray ComputedQuality assuranceKappaChemoradiotherapyEuropean journal of cancer (Oxford, England : 1990)
researchProduct

Short- and Long-Term Quality of Life and Bowel Function in Patients With MRI-Defined, High-Risk, Locally Advanced Rectal Cancer Treated With an Inten…

2015

Objective Intensified preoperative treatments have been increasingly investigated in locally advanced rectal cancer (LARC), but limited data are available for the impact of these regimens on quality of life (QoL) and bowel function (BF). We assessed these outcome measures in EXPERT-C, a randomized phase 2 trial of neoadjuvant capecitabine combined with oxaliplatin (CAPOX), followed by chemoradiation therapy (CRT), total mesorectal excision, and adjuvant CAPOX with or without cetuximab in magnetic resonance imaging-defined, high-risk LARC. Methods and Materials QoL was assessed using the European Organization for Research and Treatment of Cancer QLQ-C30 and QLQ-CR29 questionnaires. Bowel inc…

Cancer Researchmedicine.medical_specialtyOrganoplatinum CompoundsColorectal cancerHealth StatusCetuximabAntineoplastic AgentsUrinary incontinenceBowel incontinenceSeverity of Illness Indexlaw.inventionRandomized controlled trialQuality of lifelawSurveys and QuestionnairesInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansFecal incontinenceRadiology Nuclear Medicine and imagingSexual Dysfunctions PsychologicalCapecitabineRadiationRectal Neoplasmsbusiness.industryRectumChemoradiotherapy Adjuvantmedicine.diseaseMagnetic Resonance ImagingTotal mesorectal excisionNeoadjuvant TherapyhumanitiesSurgeryOxaliplatinOncologyChemotherapy AdjuvantQuality of Lifemedicine.symptombusinessFecal IncontinenceChemoradiotherapyInternational Journal of Radiation Oncology*Biology*Physics
researchProduct

Novel Approaches for Glioblastoma Treatment: Focus on Tumor Heterogeneity, Treatment Resistance, and Computational Tools

2019

BACKGROUND: Glioblastoma (GBM) is a highly aggressive primary brain tumor. Currently, the suggested line of action is the surgical resection followed by radiotherapy and treatment with the adjuvant temozolomide (TMZ), a DNA alkylating agent. However, the ability of tumor cells to deeply infiltrate the surrounding tissue makes complete resection quite impossible, and in consequence, the probability of tumor recurrence is high, and the prognosis is not positive. GBM is highly heterogeneous and adapts to treatment in most individuals. Nevertheless, these mechanisms of adaption are unknown. RECENT FINDINGS: In this review, we will discuss the recent discoveries in molecular and cellular heterog…

Cancer Researchmedicine.medical_treatmentDNA Mutational AnalysisBrain tumorBioinformaticsComplete resectionTumor heterogeneityCancer VaccinesMicrotubulesArticleClonal EvolutionMachine LearningGenetic HeterogeneityCancer stem cellAntineoplastic Combined Chemotherapy ProtocolsTumor MicroenvironmentMedicineHumansTreatment resistancePrecision MedicineDNA Modification MethylasesImmune Checkpoint InhibitorsTemozolomideModels Geneticbusiness.industryBrain NeoplasmsTumor Suppressor ProteinsBrainComputational BiologyChemoradiotherapy Adjuvantmedicine.diseasePrognosisRadiation therapyDNA Repair EnzymesOncologyDrug Resistance NeoplasmMutationTumor Suppressor Protein p53businessGlioblastomaGlioblastomamedicine.drug
researchProduct

205 Minimally invasive approaches in locally advanced cervical cancer patients undergoing radical surgery after chemoradiotherapy: a propensity score…

2020

Objectives To evaluate the oncological and surgical outcome of minimally invasive radical surgery (MI-RS) compared to open radical surgery (O-RS) in locally advanced cervical cancer (LACC) after preoperative chemoradiation (CT/RT). Methods Data relative to stage IB2-IVA cervical cancer patients managed by CT/RT and RS were retrospectively analyzed. Results Starting from 686 patients, the propensity score matching resulted in 462 cases (231 per group), balanced for FIGO stage, lymph node status, histotype, tumor grade and clinical response to CT/RT. Overall, 107 recurrences were registered with no difference in the pattern of recurrences between the two surgical approaches. The 5-year diseas…

Cervical cancermedicine.medical_specialtybusiness.industryLocally advancedDiseasemedicine.diseaseSurgerymedicine.anatomical_structurePropensity score matchingmedicineRadical surgeryStage (cooking)businessLymph nodeChemoradiotherapyPoster
researchProduct

Intensity-modulated extended-field chemoradiation plus simultaneous integrated boost in the pre-operative treatment of locally advanced cervical canc…

2015

Objective: To investigate the feasibility and determine the recommended pre-operative intensity-modulated radiotherapy (IMRT) dose of extended-field chemoradiation along with simultaneous integrated boost (SIB) dose escalation. Methods: A radiation dose of 40Gy over 4 weeks, 2Gy/fraction, was delivered to the tumour and the lymphatic drainage (planning target volume, PTV3), which encompassed a volume larger than standard (common iliac lymphatic area up to its apex, in front of the L3 vertebra), concurrently with chemotherapy (cisplatin and 5-fluorouracil). Radiation dose was escalated to the pelvis (PTV2) and to the macroscopic disease (PTV1) with the SIB-IMRT strategy. Three dose levels we…

Chemoradiotherapy; Dose Fractionation; Feasibility Studies; Female; Humans; Middle Aged; Neoplasm Staging; Preoperative Period; Prospective Studies; Radiotherapy Dosage; Radiotherapy Planning Computer-Assisted; Radiotherapy Intensity-Modulated; Treatment Outcome; Uterine Cervical Neoplasms; Radiology Nuclear Medicine and Imaging; Medicine (all)Uterine Cervical NeoplasmRadiology Nuclear Medicine and Imagingcervical cancermedicine.medical_treatmentUterine Cervical NeoplasmsMedicineHumansProspective StudiesProspective cohort studyDose FractionationSettore MED/36 - DIAGNOSTICA PER IMMAGINI E RADIOTERAPIANeoplasm StagingCervical cancerCisplatinChemotherapyFull Paperbusiness.industryMedicine (all)Radiotherapy Planning Computer-AssistedDose fractionationRadiotherapy DosageGeneral MedicineChemoradiotherapyMiddle Agedmedicine.diseaseRadiation therapyFeasibility StudieProspective StudieLymphatic systemTreatment OutcomePreoperative PeriodFeasibility StudiesFemaleDose Fractionation RadiationRadiotherapy Intensity-ModulatedbusinessNuclear medicineChemoradiotherapymedicine.drugHumanThe British journal of radiology
researchProduct

Context matters-consensus molecular subtypes of colorectal cancer as biomarkers for clinical trials

2019

Abstract The Colorectal Cancer Subtyping Consortium identified four gene expression consensus molecular subtypes, CMS1 (immune), CMS2 (canonical), CMS3 (metabolic), and CMS4 (mesenchymal), using multiple microarray or RNA-sequencing datasets of primary tumor samples mainly from early stage colon cancer patients. Consequently, rectal tumors and stage IV tumors (possibly reflective of more aggressive disease) were underrepresented, and no chemo- and/or radiotherapy pretreated samples or metastatic lesions were included. In view of their possible effect on gene expression and consequently subtype classification, sample source and treatments received by the patients before collection must be ca…

Data Analysis0301 basic medicineOncologymedicine.medical_specialtyMicroarrayconsensus molecular subtypesColorectal cancermedicine.medical_treatmentDatasets as TopicReviews03 medical and health sciencesstratification0302 clinical medicineBiasCàncer colorectalInternal medicineBiomarkers TumormedicineHumansRNA-SeqOligonucleotide Array Sequence AnalysisClinical Trials as Topicclinical trialsbusiness.industryPatient SelectionBiochemical markersbiomarkersChemoradiotherapypersonalized medicineHematologyPrognosismedicine.diseaseChemotherapy regimenPrimary tumorColorectal cancerSubtypingRadiation therapyClinical trialTreatment Outcome030104 developmental biologyOncology030220 oncology & carcinogenesisMutationgene expressionPersonalized medicineNeoplasm Recurrence LocalColorectal NeoplasmsbusinessMarcadors biomquímics
researchProduct

Soft palate preservation after tumor resection with transoral laser microsurgery

2012

Background: Management and preservation of the soft palate is dependent on clinical stage and tumor histology. However, available literature is scarce regarding the palate preservation with the use of laser CO 2 . Objectives : We report the results obtained after management with laser surgery and soft palate preservation in three patients with salivary gland neoplasms. Method: Three patients with minor salivary gland tumors were treated by means of transoral laser microsurgery. All tumors were assessed using magnetic resonance imaging. All tumors were >3 cm. Soft palate function was preserved and reconstruction was performed with primary closure. Patients began oral feeding the same day and…

Laser surgeryAdultmedicine.medical_specialtyMicrosurgerymedicine.medical_treatmentOdontologíamedicineHumansTransoral laser microsurgeryStage (cooking)General DentistryAgedSalivary glandSoft palatemedicine.diagnostic_testbusiness.industryMagnetic resonance imagingMicrosurgery:CIENCIAS MÉDICAS [UNESCO]Salivary Gland NeoplasmsCiencias de la saludSurgerymedicine.anatomical_structureOtorhinolaryngologyUNESCO::CIENCIAS MÉDICASSurgeryResearch-ArticleFemaleLaser TherapyOral SurgeryPalate SoftbusinessOrgan Sparing TreatmentsChemoradiotherapyMedicina Oral, Patología Oral y Cirugía Bucal
researchProduct

KEYNOTE-975 study design: a Phase III study of definitive chemoradiotherapy plus pembrolizumab in patients with esophageal carcinoma

2021

Despite curative-intent treatment, most patients with locally advanced esophageal cancer will experience disease recurrence or locoregional progression, highlighting the need for new therapies. Current guidelines recommend definitive chemoradiotherapy in patients ineligible for surgical resection, but survival outcomes are poor. Pembrolizumab is well tolerated and provides promising antitumor activity in patients with previously treated, advanced, unresectable esophageal/esophagogastric junction cancer. Combining pembrolizumab with chemoradiotherapy may further improve outcomes in the first-line setting. Here, we describe the design and rationale for the double-blind, Phase III, placebo-co…

Male0301 basic medicineOncologyCancer Researchmedicine.medical_specialtyClinical Trial ProtocolEsophageal Neoplasmsesophageal adenocarcinomamedicine.medical_treatmentPembrolizumabAntibodies Monoclonal Humanizedchemotherapy03 medical and health sciences0302 clinical medicineClinical ProtocolsInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineCarcinomaHumansesophageal cancerradiotherapyChemotherapybusiness.industryCancerChemoradiotherapyGeneral MedicineEsophageal cancermedicine.diseaseCombined Modality Therapyesophageal squamous cell carcinomaRadiation therapyClinical trial030104 developmental biologyOncologyResearch Design030220 oncology & carcinogenesisFemaleimmunotherapypembrolizumabbusinessChemoradiotherapyFuture Oncology
researchProduct

Session 2: Are we ready for primary chemotherapy in rectal cancer: who, when, why?

2018

The potential of preoperative chemotherapy in rectal cancer is the subject of investigation in a number of global randomized trials. In this overview and expert discussion, Professor Cervantes summarizes the findings of numerous Phase II trials testing neoadjuvant chemotherapy. The crucial points in the next phase of trials include: patient selection, whether radiotherapy can be omitted altogether and whether chemotherapy can be used to augment the initial response to chemoradiotherapy. Finally, with the emergence of Magnetic Resonance Tumour Regression Grade a reliable method for assessing response after initial chemoradiotherapy, we ask if this can be used to drive the use of further sele…

Male0301 basic medicineOncologymedicine.medical_specialtyConsensusColorectal cancermedicine.medical_treatmentRisk AssessmentDisease-Free SurvivalSession (web analytics)law.invention03 medical and health sciencesClinical Trials Phase II as Topic0302 clinical medicineRandomized controlled triallawInternal medicineAntineoplastic Combined Chemotherapy ProtocolsPreoperative CaremedicineHumansPreoperative chemotherapyChemotherapyProctectomyRectal Neoplasmsbusiness.industryGastroenterologyPrognosismedicine.diseaseMagnetic Resonance ImagingSurvival AnalysisNeoadjuvant TherapyRadiation therapyTreatment Outcome030104 developmental biology030220 oncology & carcinogenesisFemaleAugmentbusinessChemoradiotherapyColorectal Disease
researchProduct